FULC
USDFulcrum Therapeutics Inc. Common Stock
Echtzeitkurs
Kursdiagramm
Schlüsselkennzahlen
Marktkennzahlen
Eröffnung
$8.830
Hoch
$9.020
Tief
$8.300
Volumen
0.37M
Unternehmensfundamentaldaten
Marktkapitalisierung
453.0M
Branche
Biotechnologie
Land
United States
Handelsstatistiken
Durchschnittliches Volumen
0.53M
Börse
NGM
Währung
USD
52-Wochen-Spanne
Ähnliche Nachrichten
Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
― Pociredir Phase 1b PIONEER Trial Data in Sickle Cell Disease to be Presented and Published, Including 12 mg and 20 mg Cohorts ― ― Live and Webcast Investor Event with Fulcrum Leadership and Medical Experts will be
RBC Capital Maintains Sector Perform on Fulcrum Therapeutics, Raises Price Target to $7
RBC Capital analyst Luca Issi maintains Fulcrum Therapeutics with a Sector Perform and raises the price target from $5 to $7.
Piper Sandler Reiterates Overweight on Fulcrum Therapeutics, Raises Price Target to $16
Piper Sandler analyst Edward Tenthoff reiterates Fulcrum Therapeutics with a Overweight and raises the price target from $12.5 to $16.
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025
― Announced encouraging results in July 2025 from the 12 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ― ― Enrollment complete in the 20 mg dose cohort (n=12) of the
Fulcrum Therapeutics to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Wednesday, October 29, 2025, at 8:00 a.m. ET
CAMBRIDGE, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the "Company") (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives
Ähnliche Aktien
Bleiben Sie auf dem Laufenden
Preisalarme setzen, KI-Analyse-Updates und Echtzeit-Marktnachrichten erhalten.